Piramal Pharma Solutions names new Chief Operating Officer

India-based Piramal Pharma Solutions (PPS), part of Piramal Enterprises Limited, has named John Fowler as its Chief Operating Officer. In announcing the appointment, Vivek Sharma, CEO, Piramal Pharma Solutions , said that, as PPS enters into the next phase of its rapid growth, it is important to bring in seasoned executives with international experience and expertise.

Sharma further said that over a distinguished career of nearly three decades, John has successfully led several global businesses, streamlined operations, developed and implemented commercial strategies that have increased profitability while driving growth, and has aligned focus of R&D team with long term business requirements. “With our customers increasingly choosing Piramal as their ‘Partner of Choice’ to progress their assets from discovery towards commercialization, John’s track record of aligning services and talent towards a common vision, is one that the PPS team can benefit from. We are excited to have John as part of our Leadership team, welcome him, and look forward to his contributions in building strategic partnerships with our customers and propel PPS forward into the next decade,” Sharma said.

John Fowler said: “I was very impressed with the range of capabilities and the breadth of expertise that resides across PPS, and its global footprint. With external partnerships now becoming an integral part of how pharmaceutical firms and biotechs do business, I firmly believe that leading Contract Development and Manufacturing Organizations (CDMO’s), like PPS, are at an inflexion point in their growth curve. PPS is a global leader with a strong customer-centric culture, a strong focus on innovation, a robust balance sheet, a commitment towards investment, and finally, a global talent pool that combines speed with quality and delivery. As our customers seek dependable partners that can offer seamless, integrated solutions, from Discovery through Commercialization, from Drug Substance to Drug Product, I look forward to positioning PPS to deliver on these needs, and building long term, sustainable and strategic partnerships.”

Most recently, Fowler served as the Divisional CEO of the Global Fine Chemicals business at Johnson Matthey (JM), with responsibility for JM’s Services (Custom API Development, Manufacturing, Catalyst & Chiral Technologies), and Products (Generics Development and Manufacturing) portfolio. Before leading JM’s Fine Chemical Division, John held senior leadership roles in several business verticals at JM, including Pharmaceutical Materials and Services, Environmental Catalysts and Technologies, among others. John has a Chemical Engineering degree from Bucknell University and an MBA from St. Joseph University.